| Citation: | Xun Bao, Jianmei Wu, Nader Sanai, Jing Li. A liquid chromatography with tandem mass spectrometry method for quantitating total and unbound ceritinib in patient plasma and brain tumor[J]. Journal of Pharmaceutical Analysis, 2018, 8(1): 20-26.
|
| 1. | Li, Z., Xie, J., Qu, Z. et al. Advances in therapeutic drug monitoring methods based on liquid chromatography-tandem mass spectrometry | [基于液相色谱‑串联质谱技术的治疗药物监测方法研究进展]. Chinese Journal of Laboratory Medicine, 2024, 47(3): 332-340. doi:10.3760/cma.j.cn114452-20230915-00144 | |
| 2. | Blandin, A.-F., Giglio, R., Graham, M.S. et al. ALK Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma. Clinical Cancer Research, 2023, 29(14): 2651-2667. doi:10.1158/1078-0432.CCR-21-3521 | |
| 3. | Talay Pınar, P., Uzun, G., Şentürk, Z. First electrochemical investigation of new generation antineoplastic agent ceritinib at a boron-doped diamond electrode based on the pre-enrichment effect of anionic surfactant. Journal of the Iranian Chemical Society, 2023, 20(7): 1729-1742. doi:10.1007/s13738-023-02792-z | |
| 4. | Xiao, X., Xu, Y., Yu, X. et al. Discovery of imidazo[1, 2-b]pyridazine macrocyclic derivatives as novel ALK inhibitors capable of combating multiple resistant mutants. Bioorganic and Medicinal Chemistry Letters, 2023. doi:10.1016/j.bmcl.2023.129309 | |
| 5. | Köllő, Z., Garami, M., Vincze, I. et al. Therapeutic Monitoring of Orally Administered, Small-Molecule Anticancer Medications with Tumor-Specific Cellular Protein Targets in Peripheral Fluid Spaces—A Review. Pharmaceutics, 2023, 15(1): 239. doi:10.3390/pharmaceutics15010239 | |
| 6. | Jiang, J., Bao, X., Yue, Y. et al. Development and validation of a liquid chromatography coupled with tandem mass spectrometry method for determining total and unbound pamiparib in human plasma and brain tumors. Biomedical Chromatography, 2022, 36(12): e5478. doi:10.1002/bmc.5478 | |
| 7. | Cui, Y., Tan, Z., Liu, S. et al. Fragment-based discovery of novel phenyltriazolyl derivatives as allosteric type-I1/2 ALK inhibitors with promising antitumor effects. Bioorganic and Medicinal Chemistry Letters, 2022. doi:10.1016/j.bmcl.2022.128990 | |
| 8. | Mehta, S., Fiorelli, R., Bao, X. et al. A Phase 0 Trial of Ceritinib in Patients with Brain Metastases and Recurrent Glioblastoma. Clinical Cancer Research, 2022, 28(2): 289-297. doi:10.1158/1078-0432.CCR-21-1096 | |
| 9. | Maher, H.M., Almomen, A., Alzoman, N.Z. et al. Development and validation of UPLC–MS/MS method for the simultaneous quantification of anaplastic lymphoma kinase inhibitors, alectinib, ceritinib, and crizotinib in Wistar rat plasma with application to bromelain-induced pharmacokinetic interaction. Journal of Pharmaceutical and Biomedical Analysis, 2021. doi:10.1016/j.jpba.2021.114276 | |
| 10. | Niessen, W.M.A., Rosing, H., Beijnen, J.H. Interpretation of MS–MS spectra of small-molecule signal transduction inhibitors using accurate-m/z data and m/z-shifts with stable-isotope-labeled analogues and metabolites. International Journal of Mass Spectrometry, 2021. doi:10.1016/j.ijms.2021.116559 | |
| 11. | Li, Z., Guo, M., Cao, M. et al. Discovery and antitumor activity of Benzo[d]imidazol-containing 2, 4-diarylaminopyrimidine analogues as ALK inhibitors with mutation-combating effects. Bioorganic and Medicinal Chemistry, 2021. doi:10.1016/j.bmc.2021.116108 | |
| 12. | Guo, M., Zuo, D., Zhao, T. et al. Structure-based optimization identified novel furyl-containing 2, 4-diarylaminopyrimidine analogues as ALK/ROS1 dual inhibitors with anti-mutation effects. European Journal of Medicinal Chemistry, 2021. doi:10.1016/j.ejmech.2021.113259 | |
| 13. | Veerman, G.D.M., de Bruijn, P., Dingemans, A.-M.C. et al. To quantify the small-molecule kinase inhibitors ceritinib, dacomitinib, lorlatinib, and nintedanib in human plasma by liquid chromatography/triple-quadrupole mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2021. doi:10.1016/j.jpba.2020.113733 | |
| 14. | Antolčić, M., Runje, M., Galić, N. A simple and sensitive LC-MS/MS method for determination and quantification of potential genotoxic impurities in the ceritinib active pharmaceutical ingredient. Analytical Methods, 2020, 12(25): 3290-3295. doi:10.1039/d0ay00511h | |
| 15. | Lei, H., Jia, F., Cao, M. et al. An exploration of solvent-front region high affinity moiety leading to novel potent ALK & ROS1 dual inhibitors with mutant-combating effects. Bioorganic and Medicinal Chemistry, 2019, 27(20): 115051. doi:10.1016/j.bmc.2019.115051 | |
| 16. | Du, P., Guan, Y., An, Z. et al. A selective and robust UPLC-MS/MS method for the simultaneous quantitative determination of anlotinib, ceritinib and ibrutinib in rat plasma and its application to a pharmacokinetic study. Analyst, 2019, 144(18): 5462-5471. doi:10.1039/c9an00861f | |
| 17. | Lei, H., Jiang, N., Miao, X. et al. Discovery of novel mutant-combating ALK and ROS1 dual inhibitors bearing imidazolidin-2-one moiety with reasonable PK properties. European Journal of Medicinal Chemistry, 2019. doi:10.1016/j.ejmech.2019.03.038 | |
| 18. | Bao, X., Wu, J., Sanai, N. et al. Determination of total and unbound ribociclib in human plasma and brain tumor tissues using liquid chromatography coupled with tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2019. doi:10.1016/j.jpba.2019.01.017 |
Supported by:
Beijing Renhe Information Technology Co. Ltd
Xun Bao, Jianmei Wu, Nader Sanai, Jing Li. A liquid chromatography with tandem mass spectrometry method for quantitating total and unbound ceritinib in patient plasma and brain tumor[J]. Journal of Pharmaceutical Analysis, 2018, 8(1): 20-26.
DownLoad: